Highlight Therapeutics SL

Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR static1.squarespace.com/static/5e83158… #BO112 #HighlightTherapeutics #Immunotherapy #Intratumoral #melanoma

Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 static1.squarespace.com/static/5e83158… #BO112 #HighlightTherapeutics #Immunotherapy #Intratumoral #melanoma

Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer @jitc static1.squarespace.com/static/5e83158… #BO112 #HighlightTherapeutics #Immunotherapy #Intratumoral #SPOTLIGHT203 #melanoma

Breakthrough cancer treatment shows best-in-class potential to open up 2nd-line immunotherapy market to anti-PD1 resistant patients. static1.squarespace.com/static/5e83158… #BO112 #HighlightTherapeutics #Immunotherapy #Intratumoral #SPOTLIGHT203 #KEYNOTEB77 #melanoma #SITC21 #sitc2021

Join the Startup Competition of #SouthSummit15! Don't miss this opportunity goo.gl/Fci8LV

More than 18,000 people are gathered here at #AACR14 in San Diego.

The American Association for Cancer Research annual meeting is being held these days, April 5-9 in San Diego. Follow the hashtag #AACR14

Spanish biotech company Oryzon Genomics signs licensing deal with Roche. Congrats! bloomberg.com/news/2014-04-0…

Tomorrow morning a deal btw a Spanish biotech company & a big pharma will be announced according to @asebio Cant wait to know who they are!

We'll be tweeting live from the first #AACR14 press conference in about 15 minutes.

Schlegel: PIK3Calpha inhib+RAF inhib also eff vs BRAFV600E CRC. Triple combo effectively silences both MAPK & PIK3C #AACR14

BRAF Inhibs Induce Mets in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling stke.sciencemag.org/cgi/content/ab…

Deals Of The Week Looks At 2014 Takeout Targets pharmamedtechbi.com/publications/t…

@CNIO_Cancer undergraduate summer programme now open for applications. Deadline 27 April cnio.es/ing/cursos/pra…

CNIO-Merck alliance receives prize from @CFarmaceutico, Pharmacological Research and Products category cnio.es/es/news/docs/C…

Do investment bankers, CFOs, and GCs make successful Business Development Executives? Join the debate @ Allicense2014 bit.ly/1iLnaW4

Will Peter Thiel's Founder Fund put some of its new $1B fund in biotech? fiercebiotech.com/story/tech-bil…

Immuno Oncology – A 30-year Overnight Success Story biotech-now.org/health/2014/02… via @IAmBiotech

FivePrime and Bristol-Myers strike immuno-oncology deal online.wsj.com/news/articles/…

Survival improvement with #Zelboraf Rx for v600k mutated #melanoma, not just v600e mutations. ow.ly/3i09Dc